News Archive

April 2016

• Press Release Apr 29, 2016

  Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors

  If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
• 
  Story Apr 28, 2016 Discovery

  Collaborating to unlock secrets of the microbiome

  Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.

• Press Release Apr 27, 2016

  Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

  Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF  Designations support potential…
• 
  Story Apr 25, 2016 Patient Perspectives

  Patient advocacy at work: one man’s contributions to the COPD community

  Read how one caregiver established an association to provide resources for both COPD patients and caregivers.

• 
  Story Apr 25, 2016 Discovery

  Talking to: Bruno Strigini on why we're entering a transformative time in cancer care

  Accelerating Research to Get Answers Faster

• Press Release Apr 21, 2016

  Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
• Press Release Apr 21, 2016

  Novartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long terme

  Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9…
• Press Release Apr 21, 2016

  Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums

  Der Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
• Press Release Apr 20, 2016

  Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

  Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1]   Seizures are the most…
• 
  Story Apr 18, 2016 Discovery

  Factory foreman keeps liver’s line workers on task

  A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

• 
  Story Apr 14, 2016 Discovery

  How scientists aim to expand immunotherapy options for cancer patients

  Read how NIBR and Dana-Farber scientists aim to expand immunotherapy options for patients

• 
  Story Apr 13, 2016 Access to Healthcare

  A life dedicated to fighting malaria

  Lake Victoria in southwestern Kenya is on the front line in the fight against malaria, and Agnes Akoth is a key figure.